Advantages of Systematic Trunk SPECT/CT to Planar Bone Scan (PBS) in More Than 300 Patients with Breast or Prostate Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Sep 1

PMID 30167091

Citations 6

Authors

Vincent Fleury

Ludovic Ferrer

Mathilde Colombie

Daniela Rusu

Maelle Le Thiec

Francoise Kraeber-Bodere

Loic Campion

Caroline Rousseau

Affiliations

Soon will be listed here.

Abstract

Propose: The aim of our study was to evaluate the potential benefit of a systematic trunk SPECT/CT associated with a Planar Bone Scan (PBS) in breast cancer (BC) and prostate cancer (PCa) patients at initial staging or recurrence.

Results: In 328 patients, sensitivities and specificities were between 74.4-93% and 78.8-97.5% for PBS and 97.7-100% and 96.8-98.6% for SPECT/CT respectively. PBS was considered equivocal for 67 compared to only 6 patients for trunk SPECT/CT. Regardless of "optimistic" or "pessimistic" analysis of equivocal trunk SPECT/CT lesions, the trunk SPECT/CT was almost perfect, allowing to rely on this result for excluding metastatic disease which was corroborated by ROC curve analysis. The trunk SPECT/CT allowed downstaging for 62 patients (19%) and upstaging for 11 patients.

Materials And Methods: PBS and a trunk SPECT/CT were systematically performed in all patients. Independent review of PBS and trunk SPECT/CT was performed for each patient and an abnormality interpretative score (Sc) with 3 levels was built: Sc 1: metastatic or probably metastatic pattern, Sc 2: equivocal pattern, Sc 3: benign or probably benign pattern or no abnormality. The bone pattern status was defined by at least 1 year follow-up. The clinical impact was evaluated in terms of down and upstaging in patient analysis.

Conclusions: Trunk SPECT/CT improves the performance of PBS in BC and PCa assessments and results in improvements in both the detection performance of bone metastases as well as a better characterization of equivocal lesions.

Citing Articles

Whole-Body SPECT/CT: Protocol Variation and Technical Consideration-A Narrative Review.

Alqahtani M Diagnostics (Basel). 2024; 14(16).

PMID: 39202315 PMC: 11353707. DOI: 10.3390/diagnostics14161827.

Applications of SPECT/CT in the Evaluation of Spinal Pathology: A Review.

Hirsch B, Sossamon J, Khan M, Reitman C, Lawrence J, Glaser J Int J Spine Surg. 2023; 18(1):9-23.

PMID: 38050030 PMC: 11265499. DOI: 10.14444/8552.

Quantitative vs. Qualitative SPECT-CT Diagnostic Accuracy in Bone Lesion Evaluation-A Review of the Literature.

Mutuleanu M, Paun D, Lazar A, Petroiu C, Trifanescu O, Anghel R Diagnostics (Basel). 2023; 13(18).

PMID: 37761338 PMC: 10529093. DOI: 10.3390/diagnostics13182971.

Transition to Fast Whole-Body SPECT/CT Bone Imaging: An Assessment of Image Quality.

Alqahtani M, Willowson K, Fulton R, Constable C, Kench P Diagnostics (Basel). 2022; 12(12).

PMID: 36552946 PMC: 9776819. DOI: 10.3390/diagnostics12122938.

Optimization of Tc whole-body SPECT/CT image quality: A phantom study.

Alqahtani M, Willowson K, Constable C, Fulton R, Kench P J Appl Clin Med Phys. 2022; 23(4):e13528.

PMID: 35049129 PMC: 8992937. DOI: 10.1002/acm2.13528.

References

Rager O, Nkoulou R, Exquis N, Garibotto V, Tabouret-Viaud C, Zaidi H . Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup. Biomed Res Int. 2017; 2017:7039406. PMC: 5546128. DOI: 10.1155/2017/7039406. View

Abikhzer G, Gourevich K, Kagna O, Israel O, Frenkel A, Keidar Z . Whole-body bone SPECT in breast cancer patients: the future bone scan protocol?. Nucl Med Commun. 2015; 37(3):247-53. DOI: 10.1097/MNM.0000000000000427. View

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N . Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31(5):578-83. DOI: 10.1053/hp.2000.6698. View

Zhang Y, Shi H, Gu Y, Xiu Y, Li B, Zhu W . Differential diagnostic value of single-photon emission computed tomography/spiral computed tomography with Tc-99m-methylene diphosphonate in patients with spinal lesions. Nucl Med Commun. 2011; 32(12):1194-200. DOI: 10.1097/MNM.0b013e32834bd82e. View

Cook G, Azad G, Padhani A . Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging. 2016; 4(6):439-447. PMC: 5118401. DOI: 10.1007/s40336-016-0196-5. View

Even-Sapir E . Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005; 46(8):1356-67. View

Heidenreich A, Bastian P, Bellmunt J, Bolla M, Joniau S, van der Kwast T . EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2013; 65(1):124-37. DOI: 10.1016/j.eururo.2013.09.046. View

Tuncel M, Ergun E, Caglar Tuncali M . Clinical impact of SPECT-CT on bone scintigraphy in oncology: Pattern approach. J BUON. 2016; 21(5):1296-1306. View

Lofgren J, Mortensen J, Rasmussen S, Madsen C, Loft A, Hansen A . A Prospective Study Comparing Tc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with F-Fluoride PET/CT and F-Fluoride PET/MRI for Diagnosing Bone Metastases. J Nucl Med. 2017; 58(11):1778-1785. DOI: 10.2967/jnumed.116.189183. View

10.

Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck A . Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001; 42(12):1800-4. View

11.

Sharma P, Singh H, Kumar R, Bal C, Thulkar S, Seenu V . Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. Nucl Med Commun. 2011; 33(2):139-47. DOI: 10.1097/MNM.0b013e32834e3b14. View

12.

Herzig L, Bischoff T, Favrat B, Vaucher P, Gencer B, Muhlemann N . [Development, implementation and practical use of a diagnostic score]. Rev Med Suisse. 2011; 7(295):1078-80, 1082-3. View

13.

Helyar V, Mohan H, Barwick T, Livieratos L, Gnanasegaran G, Clarke S . The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2009; 37(4):706-13. DOI: 10.1007/s00259-009-1334-3. View

14.

Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S . Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2015; 55(1):59-67. DOI: 10.3109/0284186X.2015.1027411. View

15.

Giovanella L, Castellani M, Suriano S, Ruberto T, Ceriani L, Tagliabue L . Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori. 2011; 97(5):629-33. DOI: 10.1177/030089161109700515. View

16.

Romer W, Nomayr A, Uder M, Bautz W, Kuwert T . SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006; 47(7):1102-6. View

17.

Mohler J, Kantoff P, Armstrong A, Bahnson R, Cohen M, DAmico A . Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014; 12(5):686-718. DOI: 10.6004/jnccn.2014.0072. View

18.

Ndlovu X, George R, Ellmann A, Warwick J . Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies?. Nucl Med Commun. 2010; 31(7):659-65. DOI: 10.1097/MNM.0b013e3283399107. View

19.

Savelli G, Maffioli L, Maccauro M, de Deckere E, Bombardieri E . Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001; 45(1):27-37. View

20.

Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A . Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2013; 41(1):59-67. DOI: 10.1007/s00259-013-2532-6. View